SCHEDULE: 683 Capital Discloses 9.99% Stake in Gossamer Bio

683 Capital Management, LLC and Ari Zweiman have reported a 9.99% beneficial ownership stake in Gossamer Bio, Inc. as of June 11, 2026.

Summary

• 683 Capital Management, LLC, 683 Capital Partners, LP, and Ari Zweiman filed a Schedule 13G reporting a combined beneficial ownership of 49,868,571 shares of Gossamer Bio, Inc. common stock.
• The reported stake represents 9.99% of the company's outstanding common stock.
• The holdings consist of 39,504,484 shares of common stock, 9,102,055 shares issuable upon exercise of warrants, and 1,262,032 shares issuable upon conversion of convertible notes.
• The filing confirms the securities were acquired for investment purposes without the intent to change or influence control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development, as it reflects institutional interest and confidence in the company's equity, though it is a standard regulatory disclosure rather than a fundamental business update.

Positives

• Significant institutional investment from 683 Capital Management, signaling confidence in the company's long-term prospects.
• The reporting persons have explicitly stated they are not seeking to change or influence control of the issuer.

Negatives

• The 9.99% ownership stake is subject to a beneficial ownership limitation, which may restrict the immediate conversion of certain notes or exercise of warrants if it pushes the holder above that threshold.

Risks

• Potential for future dilution if warrants and convertible notes are exercised or converted.
• Market sensitivity to large institutional holders adjusting their positions.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the company's operations, but confirms the reporting persons' intent to hold the securities for investment purposes.

Management Comments

• The reporting persons certify that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings by specialized investment firms like 683 Capital in the biotech sector often indicate a strategic bet on clinical trial outcomes or pipeline development, reflecting broader market interest in small-cap pharmaceutical growth.

Comparison to Industry Standards

• The 9.99% ownership threshold is a standard reporting level for institutional investors to avoid triggering more stringent 'activist' reporting requirements under Schedule 13D.
• The inclusion of warrants and convertible notes in the beneficial ownership calculation is standard practice for institutional investors in the biotech space to maintain accurate reporting of potential equity exposure.

Stakeholder Impact

• Shareholders may view the entry of a significant institutional investor as a validation of the company's value proposition.
• Potential for increased volatility if the reporting persons decide to divest their position.

Next Steps

• Monitoring of future SEC filings for any changes in the reporting persons' position or intent.

Key Dates

Keywords

Gossamer Bio, 683 Capital, Schedule 13G, Institutional Ownership, Biotech Investment, Common Stock